.gif)
Cancer Research UK scientists have found how cells adapt to overcome cancer drugs designed to interfere with their genetic controls, according to a study published today (Wednesday) in Epigenetics and Chromatin.
Scientists in Korea have discovered that using antibacterial soap when hand-washing is no more effective than using plain soap, according to a paper published today in the Journal of Antimicrobial Chemotherapy.
Food craving may be 'hard-wired' in the brain of overweight patients, say scientists who found that obesity is associated with neural changes similar to those found in substance addiction.
Sun Pharmaceutical Industries Ltd. announced that one of its subsidiary has entered into an agreement and plan of merger with InSite Vision Inc. (InSite Vision) under which a Sun Pharma subsidiary has offered to acquire InSite Vision. InSite Vision focuses on developing new specialty ophthalmic products, including three late stage programs. Sun Pharma is in the process of establishing a branded ophthalmic business in the US. This proposed acquisition of InSite Vision, coupled with the recent in-licensing of Xelpros™ (Latanoprost BAK-free eye drops) in June 2015, are steps in this direction. These deals give Sun Pharma access to four late stage branded ophthalmic products in the US.
InSite Vision has developed the DuraSite® and DuraSite2® drug delivery platforms which are capable of extending the duration of drug retention, thus resulting in lower dosing frequency, and potentially enhanced efficacy. Based on this technology, InSite Vision has developed a pipeline of late-stage clinical candidates, and has recently filed a New Drug Application (NDA) with the US FDA for BromSite™ (0.075% bromfenac) for the treatment of inflammation and prevention of pain associated with cataract surgery. It plans to file another NDA in 2017 for DexaSite™ (0.1% dexamethasone) for the treatment of non-bacterial blepharitis, a common ocular condition for which there is no approved product currently available. It’s AzaSite Plus™ is currently in Phase-3 clinical development for the treatment of eye infections, and ISV-101 is in Phase 1/2 clinical development for dry-eye disease and inflammation.
InSite Vision also has two commercialized products based on its innovative DuraSite® platform approved for the treatment of bacterial eye infections, AzaSite®(azithromycin ophthalmic solution) 1%, and Besivance® (besifloxacin ophthalmic suspension) 0.6%, marketed by respective partners.
Commenting on the deal, Jerry St. Peter, Vice President & Head of Sun Pharma’s U.S. Ophthalmic Business said “The potential addition of the InSite Vision portfolio serves as a significant step towards enhancing our branded specialty pipeline in the Ophthalmic segment. InSite Vision will bring with it a pipeline of three late-stage clinical candidates, validated drug delivery technology and a track record of achieving US FDA approval for ophthalmic products.”
Kal Sundaram, CEO of Sun Pharma’s North American Business said “This potential acquisition is a part of our overall objective of transitioning to a specialty company. Besides Dermatology, we have identified Ophthalmics as one of the key segments for establishing our branded presence in the U.S.”
Under the terms of the agreement and plan of merger, an indirect wholly owned subsidiary of Sun Pharma will commence a tender offer for all of the issued and outstanding common stock of InSite Vision at a price of USUSD 0.35 per share in cash, a 30% premium to the implied price per share under the terminated ‘Amended and Restated Agreement and Plan of Merger’ between InSite Vision and a competing bidder for InSite Vision’s common stock based on the stock price of the competing bidder as of September 11, 2015. The transaction has a total equity value of approximately USUSD 48 million on fully diluted basis plus related debt and other transaction costs assuming all shares of InSite Vision are tendered in the offer. The transaction has been approved by the board of directors of the Sun Pharma subsidiary. InSite Vision’s board of directors has also approved the transaction and unanimously recommended that its stockholders tender their shares pursuant to the tender offer.
For the 6 month period ended June 30, 2015, InSite Vision recorded revenues of USUSD 3.8 million, an EBITDA loss of USUSD 6.4 million and a net loss of USUSD 7.5 million.
The acquisition is subject to InSite Vision’s stockholders tendering at least a majority of InSite Vision’s outstanding shares (determined on a fully diluted basis), or, alternatively, InSite Vision stockholders representing a majority of the outstanding shares of InSite Vision’s common stock voting to approve the transaction as required by applicable law, in addition to other customary closing conditions. The acquisition is expected to close in the fourth quarter of 2015.
Subscribe to PharmaTutor News Alerts by Email >>
A new research revealed that the part of the brain is smaller in people who regularly consume junk food. The study was published in BMC Medicine.
A new group of antibiotics that may provide relief to people affected by antibiotic resistance, has been developed by a team of researchers from Virginia Institute of Technology. These new antibiotics can successfully target the bacteria Staphylococcus aureus (staph) and the antibiotic-resistant strains commonly known as methicillin-resistant Staphylococcus aureus (MRSA). The paper was published in Medicinal Chemistry Communications.
A new study revealed that Social factors such as marital status, insurance status, and income may affect the chances of survival in young patients with Acute myelogenous leukemia (AML). The study appeared online in CANCER.
Scientists from University of Iowa found two natural compounds one found in apples and one in green tomatoes, which reduce the protein's activity in aged muscle. The protein called ATF4 alters gene expression in skeletal muscle, causing reduction of muscle protein synthesis, strength and mass.
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
